Clinical Trials Logo

Cervical Squamous Cell Carcinoma clinical trials

View clinical trials related to Cervical Squamous Cell Carcinoma.

Filter by:

NCT ID: NCT06232083 Recruiting - Immunotherapy Clinical Trials

Application of PLDR External Irradiation Combined With Immune Checkpoint Inhibitors in Recurrent Cervical Cancer

Start date: February 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

At present, the treatment methods for recurrent cervical cancer are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent cervical cancer, but the clinical response rate is insufficient. Pulse low-dose rate radiotherapy (PLDR) is a new technology in recent years, which uses continuous pulse low-dose rate irradiation to induce hypersensitivity in tumors, and its clinical safety has been verified. Compared to conventional radiotherapy, PLDR has advantages in protecting the lymphatic system and relieving the immune barrier, but it is still unclear whether it can improve the efficacy of ICB. This project aims to combine PLDR with ICB to explore new strategies for recurrent cervical cancer.

NCT ID: NCT05613283 Active, not recruiting - Cervical Cancer Clinical Trials

Primary Cervical Cancer Screening by Self-sampling HPV Test

PREVENT
Start date: November 19, 2022
Phase:
Study type: Observational

Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider, which is labor consuming and the coverage and compliance are both relatively low in some areas. Non-invasive hrHPV self-sampling test appears to be more acceptable and may improve the HPV screening coverage. This study aims to evaluate the clinical performance of a newly developed urine/vaginal self-sampling hrHPV test in Cervical cancer screening.

NCT ID: NCT05210348 Recruiting - Cervical Cancer Clinical Trials

Clinical Evaluation of Detection of High Risk HPV in Urine

Urine-hrHPV
Start date: September 15, 2021
Phase:
Study type: Observational

Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer. Traditional HPV testing is based on the cells sample shed from the cervix. Recent studies have shown that urine HPV detection can be used as a new HPV detection method. This study intends to include patients undergoing TCT /HPV test/colposcopy in the department of gynecological diseases of the hospital, and collect urine samples and cervical swab samples. Sanger sequencing and cervical swab HPV test results were compared to evaluate the accuracy and clinical validity of urine HPV test combined with clinical diagnosis results of cases.

NCT ID: NCT05013268 Not yet recruiting - Clinical trials for Cervical Squamous Cell Carcinoma

Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma

TiTanec
Start date: September 2021
Phase: Phase 1
Study type: Interventional

The goal of this clinical trail is to investigate the efficacy and safety of PD-1 antibody Tislelizumab plus TP regimen (taxane combined with platinum) as neoadjuvant therapy for patients diagnosed as local advanced cervical carcinoma (FIGO staging IB2-IIB).

NCT ID: NCT04976478 Not yet recruiting - Clinical trials for Cervical Squamous Cell Carcinoma

Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma

Start date: July 2021
Phase:
Study type: Observational [Patient Registry]

To evaluate the efficacy and safety of Nimotuzumab combined with IMRT in elder patients with locally advanced cervical squamous cell carcinoma

NCT ID: NCT04678791 Not yet recruiting - Clinical trials for Cervical Squamous Cell Carcinoma

Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma

Start date: December 2020
Phase: N/A
Study type: Interventional

To investigate the efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of local advanced cervical squamous cell carcinoma.

NCT ID: NCT03983954 Active, not recruiting - Prostate Cancer Clinical Trials

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Start date: October 10, 2019
Phase: Phase 1
Study type: Interventional

This is a dose escalation, MTD expansion (Phase 1b) and cohort expansions (Phase 2) study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.

NCT ID: NCT03738228 Active, not recruiting - Clinical trials for Cervical Adenocarcinoma

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Start date: January 7, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies how well atezolizumab before and/or with standard of care chemoradiotherapy works in immune system activation in patients with stage IB2, II, IIIB, or IVA cervical cancer that has spread to the lymph nodes. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab before and/or with chemoradiotherapy may lower the chance of tumors growing or spreading.

NCT ID: NCT02646319 Completed - Clinical trials for Stage IV Breast Cancer

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

Start date: January 2016
Phase: Early Phase 1
Study type: Interventional

This pilot trial studies how well nanoparticle albumin-bound rapamycin works in treating patients with cancer that as has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced cancer) and that has an abnormality in a protein called mechanistic target of rapamycin (mTOR). Patients with this mutation are identified by genetic testing. Patients then receive nanoparticle albumin-bound rapamycin, which may stop the growth of cancer cells by blocking the mTOR enzyme, which is needed for cell growth and multiplication. Using treatments that target a patient's specific mutation may be a more effective treatment than the standard of care treatment.

NCT ID: NCT02562729 Completed - Clinical trials for Cervical Adenocarcinoma

Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer

Start date: September 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the feasibility of complete nerve-sparing type C1 radical hysterectomy in cervical cancer.